| 发明名称 |
PHARMACEUTICAL AGENT |
| 摘要 |
<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical agent suppressing nervous function disorders by inhibiting chronic progression of Parkinson's disease or protecting dopamine neurocytes from etiology thereof to extend a period by time of L-DOPA administration, and having function-improving effect. <P>SOLUTION: The pharmaceutical agent includes a quinolone compound represented by general formula (1). In the formula: R<SB POS="POST">1</SB>is hydrogen or the like; R<SB POS="POST">2</SB>is hydrogen or the like; R<SB POS="POST">3</SB>is a phenyl group or the like which may have a substituent; R<SB POS="POST">4</SB>is halogen or the like; R<SB POS="POST">5</SB>is hydrogen or the like; R<SB POS="POST">6</SB>is hydrogen or the like; and R<SB POS="POST">7</SB>is hydrogen or the like. <P>COPYRIGHT: (C)2012,JPO&INPIT |
| 申请公布号 |
JP2012012388(A) |
申请公布日期 |
2012.01.19 |
| 申请号 |
JP20110125191 |
申请日期 |
2011.06.03 |
| 申请人 |
OTSUKA PHARMACEUT CO LTD |
发明人 |
OTSUBO KENJI;YAMAUCHI TAKAHITO;OCHI YUJI |
| 分类号 |
A61K31/706;A61K31/47;A61K31/4709;A61K31/473;A61K31/4741;A61K31/4745;A61K31/496;A61K31/506;A61K31/5377;A61K31/551;A61K31/553;A61K31/675;A61P25/16;A61P25/28;A61P43/00;C07D215/26;C07D215/48;C07D221/10;C07D221/16;C07D401/04;C07D401/06;C07D401/12;C07D405/04;C07D405/12;C07D409/04;C07D413/14;C07D471/04;C07D491/048;C07D491/052;C07H19/04 |
主分类号 |
A61K31/706 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
|
| 地址 |
|
